Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02654717 | Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp | PHASE2 | COMPLETED | 111 | — | — | Nov 1, 2015 | Aug 1, 2016 | Mar 17, 2020 | 3 | Germany |
Percent of patients with complete clearance of actinic keratosis (AK) lesions at the end of treatment (8 weeks)
| Arm | Type | Description |
|---|---|---|
| DFD-07 cream | EXPERIMENTAL | DFD-07 cream applied twice daily |
| Placebo cream | PLACEBO_COMPARATOR | Placebo cream applied twice daily |
| Name | Type | Description |
|---|---|---|
| DFD-07 Cream | DRUG | - |
| Placebo Cream | DRUG | - |
Inclusion Criteria: To be eligible for the study, the patients have to fulfil all of the following criteria at Visit 1: 1. Written informed consent has been signed and dated prior to any study related procedure or initiation of a wash out period 2. Skin type I, II or III according to Fitzpatrick 3...